DCGI approves commercial launch of Tata Group's low-cost COVID-19 test 'Feluda'

This test uses an indigenously-developed, cutting-edge CRISPR technology for detecting the virus' genome sequence

Press Trust of India September 20, 2020 17:32:12 IST
DCGI approves commercial launch of Tata Group's low-cost COVID-19 test 'Feluda'

Representational image. AFP

New Delhi: The Drugs Controller General of India (DGCI) has approved the commercial launch of 'Feluda', the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) said on Saturday.

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.

"The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use," the statement added.

CRISPR is a genome editing technology to diagnose diseases. The technology has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).

"The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from DCGI for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 percent specificity for detecting novel coronavirus ," the statement said.

The Tata CRISPR test is the world's first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing COVID-19 , it said.

Moreover, CRISPR is a "futuristic" technology that can also be configured for detection of multiple other pathogens in the future.

"The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up COVID-19 testing quickly and economically, with a 'Made in India' product that is safe, reliable, affordable and accessible," the statement added.

Commenting on the development, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd said, "The approval for the Tata CRISPR test for COVID-19 will give a boost to the country's efforts in fighting the global pandemic.

"The commercialisation of Tata CRISPR test reflects the tremendous R&D talent in the country which can collaborate to transform India's contributions to the global healthcare and scientific research world," he said.

Anurag Agrawal, director, CSIR-IGIB, said the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2.

He emphasised that this shows the interconnectedness of scientific knowledge and technology and the innovation of the young research team led by Debojyoti Chakraborty and Souvik Maiti.

Updated Date:

also read

COVID-19 outbreak in Karnataka: 33 students at Bengaluru boarding school, 178 at Dharwad medical college test positive
India

COVID-19 outbreak in Karnataka: 33 students at Bengaluru boarding school, 178 at Dharwad medical college test positive

As many as 33 students, aged below 18, and a staffer at a private boarding school at Dommasandra in Bengaluru’s Whitefield have tested positive for coronavirus

India reports 8,954 new COVID-19 infections; active cases fall below one lakh after 547 days
India

India reports 8,954 new COVID-19 infections; active cases fall below one lakh after 547 days

The health ministry reported that the national coronavirus recovery rate has improved to 98.36 percent, the highest since March 2020

India reports 8,603 fresh COVID-19 infections, toll climbs to 4,70,530 with 415 fatalities
India

India reports 8,603 fresh COVID-19 infections, toll climbs to 4,70,530 with 415 fatalities

The active coronavirus caseload declined to 99,974, comprising 0.29 percent of the total infections, the lowest since March 2020